Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

1032 Background: SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in women with ER+, HER2− advanced breast cancer (ABC). Parts A/B (escalation/expansion) assessed camizestrant monotherapy and have been presented previously. Parts C/D examine camizestrant in combination with palbociclib; here we present mature data from camizestrant 75 mg in combination with palbociclib; 75 mg being the camizestrant dose currently under investigation in the Phase 3 studies SERENA-4 (NCT04711252) and SERENA-6 (NCT04964934). Methods: The primary objective was to determine the safety and tolerability of camizestrant once daily (QD) with palbociclib. Secondary objectives included anti-tumor response and pharmacokinetics (PK). Prior treatment with < 2 lines of chemotherapy in the advanced setting was permitted. There was no limit on the number of lines of prior endocrine treatment in the advanced setting; prior treatment with CDK4/6 inhibitors and fulvestrant (F) was permitted. Results: As of 9 September 2021, 25 patients had received camizestrant 75 mg QD in combination with palbociclib. Tolerability of the combination of camizestrant 75 mg and palbociclib was consistent with that of each drug individually. No patient required camizestrant dose interruption/reduction/discontinuation due to a camizestrant-related adverse event (AE); moreover, none experienced a Grade ≥3 camizestrant-related AE. All camizestrant-related heart rate reductions were Grade 1 (asymptomatic). All camizestrant-related visual effects were Grade 1 (mild), apart from one patient who experienced transient Grade 2 (moderate) visual effects that resolved to Grade 1 without dose modification. Camizestrant-related gastrointestinal disorders were all Grade 1, except one instance of Grade 2 nausea lasting one day. PK data for camizestrant 75 mg QD and palbociclib combined were broadly consistent with camizestrant as monotherapy and published palbociclib steady-state PK data, further supporting the use of camizestrant 75 mg QD (Phase 3 dose) in combination with the approved palbociclib doses. In these heavily pre-treated patients (48% prior chemotherapy, 80% prior CDK4/6i, 68% prior F; all in advanced disease setting) and of whom 60% had visceral metastases, the clinical benefit rate at 24 weeks was 7/25 (28%). Conclusions: The PK and safety profile of camizestrant 75 mg QD in combination with palbociclib is favorable in this mature Phase 1 dataset. Despite extensive pre-treatment - including chemotherapies, CDK4/6i, and F - camizestrant 75 mg QD in combination with palbociclib exhibits encouraging clinical activity. The results from the ongoing Phase 3 studies, SERENA-4 and SERENA-6, will further elucidate the role of this combination in the treatment of patients with HR+/HER2− ABC. Clinical trial information: NCT03616587.